TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
BALTIMORE–(BUSINESS WIRE)—- $TNFA–TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results from the first stage of … Read more
